间充质基质细胞治疗ARDS的安全性和有效性:随机对照试验的荟萃分析
该研究为随机对照试验的荟萃分析,方案注册于Open Science Framework,检索Pubmed和Embase,纳入13项RCT共655例ARDS患者,比较静脉输注间充质基质细胞(MSC)与对照的疗效与安全性。结果显示MSC组不良事件与对照无显著差异(OR=0.64,95%CI [0.34, 1.20],P=0.17,I2=0%),MSC可降低ARDS死亡率(OR=0.66,95%CI [0.46, 0.96],P=0.03,I2=10%)。作者认为MSC的安全性不劣于标准治疗,可能降低ARDS死亡率,但主要结果异质性虽低(I2<25%),仍需更多高质量、大规模临床试验进一步证实。
要点
- 13项RCT共655例ARDS患者,MSC组死亡率低于对照(OR=0.66,95%CI [0.46, 0.96],P=0.03,I2=10%)。
- MSC组不良事件与对照无显著差异(OR=0.64,95%CI [0.34, 1.20],P=0.17,I2=0%),安全性不劣于标准治疗。
- 纳入标准为静脉输注MSC对比对照的RCT,剂量不限,语言不限。
- 主要结果异质性低(I2<25%),但作者指出仍需更多高质量、大规模临床试验进一步证实。
适用人群与场景
- 急性呼吸窘迫综合征(ARDS)患者,包括COVID-19诱导的ARDS;纳入静脉输注MSC对比对照的RCT,剂量不限。
处置流程与药物剂量
- MSC与对照均为静脉输注,剂量不限。
研究设计与关键结果
- 研究类型:随机对照试验的荟萃分析,方案注册于Open Science Framework;检索Pubmed和Embase,无语言限制,按PICOs原则;共纳入13项RCT、655例ARDS患者。
- 主要安全性终点:MSC组与对照组不良事件无显著差异(OR=0.64,95%CI [0.34, 1.20],P=0.17,I2=0%)。
- 疗效终点:与对照相比,MSC可降低ARDS死亡率(OR=0.66,95%CI [0.46, 0.96],P=0.03,I2=10%)。
- 异质性评估采用χ2检验,P<0.05认为显著;根据各分析的I2值选择固定效应或随机效应模型。
证据类型、等级与局限
- 证据类型:随机对照试验的荟萃分析。
- 作者结论:MSC的安全性不劣于标准治疗,可能降低ARDS死亡率。
- 局限:主要结果异质性虽低(I2<25%),仍需更多高质量、大规模临床试验进一步证实。
对床旁实践的改变
- 作者认为MSC的安全性不劣于标准治疗,可能降低ARDS死亡率;仍需更多高质量、大规模临床试验进一步证实。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Mesenchymal stromal cells (MSC) have shown potential efficacy in both animal and human trials of acute respiratory distress syndrome (ARDS). Especially during the COVID-19 pandemic, MSC was intensely studied for treating COVID-19-induced ARDS. The purpose of this study is to evaluate the safety and efficacy of MSC in ARDS via a meta-analysis of randomized controlled trials (RCTs). Therefore, a meta-analysis of RCTs of MSC as a therapy for ARDS was conducted. The protocol of this review was registered on Open Science Framework. With no language restriction and according to the "PICOs" principle, searches were conducted on Pubmed and Embase to retrieve any clinical literature on MSC for ARDS. Any RCT, which compared MSC to controls for ARDS, where MSC and controls were intravenously infused, of any dosage, was eligible for inclusion. A total of 13 RCTs, which evaluated MSC versus control for treating ARDS, enrolling a total of 655 cases, met the inclusion criteria and appeared in this meta-analysis. A heterogeneity assessment was carried out using the χ2 test, where a P value less than 0.05 was considered significant. The choice of a fixed-effect or a random-effect model was decided by the I2 value in each of the analyses. This meta-analysis indicated that there was no significant difference in terms of adverse events between MSC and control for ARDS (OR = 0.64, 95% CI [0.34, 1.20], P = 0.17, and I2 = 0%). In comparison with control, MSC could reduce the mortality of ARDS (OR = 0.66, 95% CI [0.46, 0.96], P = 0.03, and I2 = 10%). Based on the results of our meta-analysis, the safety of MSC was demonstrated to be non-inferior to that of standard treatment, and MSC may reduce the mortality rate of ARDS. Though the heterogeneity in the main results was low (I2 < 25%), more high-quality and large-scale clinical trials are needed to further confirm our findings.
参考来源
- Wang F, Li Y, Wang B, et al. The safety and efficacy of mesenchymal stromal cells in ARDS: a meta-analysis of randomized controlled trials. Crit Care. 2023. PMID: 36670442. doi:10.1186/s13054-022-04287-4
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。